Join Seattle PBSS on November 3 for: ๐๐ฟ๐ผ๐บ ๐ฃ๐ฟ๐ฒ๐ฐ๐น๐ถ๐ป๐ถ๐ฐ๐ฎ๐น ๐๐ผ ๐๐น๐ถ๐ป๐ถ๐ฐ๐ฎ๐น: ๐๐ฐ๐ฟ๐ผ๐๐ ๐ง๐ต๐ฒ๐ฟ๐ฎ๐ฝ๐ฒ๐๐๐ถ๐ฐ ๐ ๐ผ๐ฑ๐ฎ๐น๐ถ๐๐ถ๐ฒ๐
This full-day workshop will bring together experts across different therapeutic modalities to talk about what actually matters when making the jump from preclinical development to clinical proof of concept.
Weโll dig into questions like:
๐ฌ What preclinical data do you really need before moving forward?
๐ What data are nice to have, but perhaps not worth losing sleep over?
๐ How do clinical design, planning, dose selection, and execution change depending on the modality?
๐ญ And what does the evolving guidance around animal use in preclinical development mean for clinical planning and dose selection?
In other words, this is about the fascinating, sometimes complicated space between โ๐๐ต๐ฒ ๐ฑ๐ฎ๐๐ฎ ๐น๐ผ๐ผ๐ธ ๐ฝ๐ฟ๐ผ๐บ๐ถ๐๐ถ๐ป๐ดโ and โ๐น๐ฒ๐โ๐ ๐ฝ๐๐ ๐๐ต๐ถ๐ ๐ถ๐ป๐๐ผ ๐ฎ ๐ฐ๐น๐ถ๐ป๐ถ๐ฐ๐ฎ๐น ๐๐ฟ๐ถ๐ฎ๐น.โ
And we have a fantastic group of speakers joining us:
Vinita Uttamsingh, PhD, Novo Nordisk | Michael Z. Liao, PhD, MLS, Third Arc Bio | Kamal D. Puri, PhD, OncoResponse | Melissa DeFrancesco, Ph.D., Lyell Immunopharma | Heather Webb Hsu, PhD, Inipharm | Peter Korytko, PhD, Preclinical GPS
Expect plenty of practical insights, real-world experience, and conversations about what it takes to successfully navigate the preclinical-to-clinical transition. ๐
๐
November 3, 2026
โฐ 11:30 AM โ 6:00 PM PT
๐ Alexandria Life Science, 1150 Eastlake Ave E, Seattle
๐ Free parking provided
โ Light refreshments, beverages, and happy hour snacks provided
๐ Register here: https://www.pbss.org/eventDetails/1076